Axovia, an innovative gene therapy company developing disease-transformative medicines for ciliopathies, is a majority-owned subsidiary of Jaguar Gene Therapy, which is backed by Deerfield Management and UCL Technology Fund.
AlbionVC leads a £14m Series A investment into Solidatus, next generation data management platform, alongside HSBC Ventures and Citi.
UCL Technology Fund portfolio company Quell Therapeutics, a biotechnology firm developing engineered T regulatory cell therapies, expands Series A financing to $84 Million.
AlbionVC portfolio company Limitless, announces $10m Series B and adds Genesys as a new investor and technology partner to continue US expansion.
UCL Technology Fund is delighted to announce that Leigh Brody, PhD and Dominik Leisi have joined the fund’s life sciences investment team.
Nadine Torbey, investor at AlbionVC discusses lessons learnt from working with early stage startups with the Silicon Republic.
Phasecraft, a UCL Technology Fund portfolio company is taking quantum theory from research to reality, faster. Today it announces the largest seed funding round for a UK quantum computing company from a syndicate of new and existing investors.
DYSIS Medical announces reimbursement rates of $54.4 for computer-aided mapping of the cervix that will help increase patient access to DYSIS cervical mapping technology.
